Get it on Google Play

FDA approves Revolution Medicines' daraxonrasib for pancreatic cancer

August 26, 2026 12:59 PM EDT Send to a Friend
Revolution Medicines, Inc. (Nasdaq: RVMD) announced that the U.S. Food and Drug Administration has approved RASONQUE (daraxonrasib), a once-daily oral ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login